Chemotherapy and Drug Information

Pregnancy Screening Inconsistent in Female Adolescents Before Chemotherapy Exposure

Pregnancy Screening Inconsistent in Female Adolescents Before Chemotherapy Exposure

Pregnancy screening rates before teratogenic exposures are low for female adolescent patients with acute leukemia and those with ER visits including abdominal/pelvic CT.

New Class of Drugs Shows Promise Against Kidney Cancer

New Class of Drugs Shows Promise Against Kidney Cancer

A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.

Drug Prevents Heart Damage in Pediatric Patients Receiving Chemotherapy

Drug Prevents Heart Damage in Pediatric Patients Receiving Chemotherapy

Dexrazoxane has cardioprotective properties that can prevent long-term cardiotoxicity in pediatric patients receiving chemotherapy, according to a review of the medical literature on cardiotoxic effects of anthracycline treatment.

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

Chemotherapy-Induced Dormancy Improves Immunotherapy for Breast Cancer

Inducing quiescent dormancy with conventional chemotherapy makes cancer cells more susceptible to immunotherapy, thereby minimizing potential for tumor recurrence.

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

Managing IRAEs in Patients Receiving Checkpoint Inhibitors

How should side effects of the new checkpoint inhibitor drugs be managed?

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.

Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer

Danish researchers identified a microRNA shown to predict whether a patient with colorectal cancer would be resistant to oxaliplatin treatment, a discovery that holds promise of improving both current treatment options and development of future treatment strategies.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

Managing Toxicity Risks of Dose-Dense Chemotherapy in the Obese

Managing Toxicity Risks of Dose-Dense Chemotherapy in the Obese

Risks for severe toxicities in obese patients receiving dose-dense chemotherapy are associated with measures used to determine dose, according to a retrospective evaluation of select participants in the GAIN study.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin) - cervical cancer

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs